Skip to main content
Equibles
MTNB logo

MTNB · Matinas BioPharma Holdings, Inc.

Track MTNB — free

Use MTNB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MTNB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.85 +0.03 (+1.06%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.48M
Shares
979,520
Volume · Oct 5 183.97K Avg daily vol (6 sessions) 259.9K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.82 Open$2.78 Day$2.43–3.00 Available close range$2.42–12.15 Avg vol available · 7d223K Short int29K · 3.0% float · 1.0d Short vol55% Last earningsAug 14, 2024 DataMay 2026–Oct 2026 Filing10-Q · Aug 13

The closing range uses available history since May 29, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026
Q2 2024 earnings call transcript
call held Aug 14, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$6.69M
Trailing 12 months
Revenue growth YoY
-65.6%
Year over year
Operating margin
-2,168.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
52-week position 4%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-11% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.00% of float · ▲ +41.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Squeeze score 47
elevated · 0–100
Fundamentals
Weak
Revenue growth −20%
Y/Y
EPS growth +60%
Y/Y
Free cash flow $-7.2M
Quant / Vol
risk profile
Very High
Volatility 551%
annualized · 1-yr
Max drawdown −80%
past year

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 1 · 0
50 / 200-day cross
No cross Neutral
52-week position
4% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-11% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.00% of float · ▲ +41.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Price context
position in its available closing range
Range low $2 Now $3 · 4% Range high $12

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MTNB
Matinas BioPharma Holdings, Inc.
this stock
$2.48M — -20.0% — 3.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
25
% held
2.2%
Net QoQ
-2.0K sh
Top holder
RENAISSANCE TECHNOLOGIES…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
29.4K
Days to cover
1.0d
Change
+8.7K sh
View
Short Volume
Short vol %
55%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
34.2K
Value
$6.5K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
May 25, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.1M
Net income (FY)
$-10.3M
EPS diluted
$-30.00
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 28, 2026
This year
11
View
Exempt Offerings
Offering
$3.3M
Filed
Feb 19, 2025
View
Earnings & Events
Webcasts
Last webcast
Aug 14, 2024
View

Performance

5D 20D 120D MTD YTD
MTNB +11.5% — — +10.6% —
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY +10.3% — — +9.0% —
Key facts CIK 1582554 CUSIP 576810303 13F (30d) 1 filings 1 filers Visit website Investor relations